Launching Cagrisema and Amycretin ahead of the patent expiry for Semaglutide could ensure Novo Nordisk maintains a competitive edge in the obesity treatment market. This proactive approach not only showcases their commitment to innovation but also potentially secures a seamless transition in market dominance from Semaglutide to the new drugs, mitigating risks associated with patent cliffs.